Naftopidil
![]() | |||
(IUPAC) ime | |||
---|---|---|---|
1-[4-(2-metoksifenil)piperazin-1-il]-3-(1-naftiloksi)propan-2-ol | |||
Klinički podaci | |||
AHFS/Drugs.com | Internacionalno ime leka | ||
Identifikatori | |||
CAS broj | 57149-07-2 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 4418 | ||
UNII | R9PHW59SFN ![]() | ||
Hemijski podaci | |||
Formula | C24H28N2O3 | ||
Mol. masa | 392,49 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | ℞ Prescription only | ||
Način primene | Oralno |
Naftopidil (Flivas) je antihipertenziv koji deluje kao selektivni antagonist α1-adrenergičkog receptora ili alfa blokator.[3]
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, Matsuya F, Shida Y, Nishimura N, Yogi Y, Tsurusaki T, Takehara K, Nomata K, Shiraishi K, Shono T, Aoki D, Kanetake H. (2011). „Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication”. Hinyokika Kiyo. 57: 7-13.
Povezano
- Urapidil
Spoljašnje veze
![]() | Portal Medicina |
![]() | Portal Hemija |
- p
- r
- u
Simpatolitički (i blisko srodni) antihipertenzivi (C02)
(antagoniziraju α-adrenergičku
vazokonstrikciju)
Centralni |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Periferalni |
|
|